16-186 - Pembrolizumab and Chemoradiation Treatment for Advanced Cervical CancerStatus: open
A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer
Treatment for Cervical Cancer
The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation. IRB Number 16-186
SponsorsThis trial is sponsored by Merck.
Providers Associated With This Trial
- Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistAssociate Director for Clinical Research; Professor of Interdisciplinary Clinical Oncology